Sanofi's Dupixent has set a high standard of care, generating a market value exceeding $10 billion while treating less than 10% of the moderate-to-severe AD patient population. B.Riley suggests ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

Sanofi’s Dupixent (dupilumab ... major drivers of the persistent underlying inflammation in atopic dermatitis (AD). The medicine is being jointly developed by Regeneron and Sanofi under a ...

Sanofi's Dupixent has set a high standard of care, generating a market value exceeding $10 billion while treating less than 10% of the moderate-to-severe AD patient population. B.Riley suggests that ...